Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)

Health and Healthcare

Published: November 3, 2011 10:59 am

Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals. It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate.

Its shares are up more than 100% after clinical data on its prostate cancer drug candidate showed to be so effective. Medivation has even halted the clinical trial so that it can give the medicine to all participants.

The MDV3100 tial was in the final development stage for potential U.S. FDA marketing approval. The interim data indicated that patients lived an average of 4.8 months longer than those on a placebo.

That is going to only be added pressure for Dendreon Corporation (NASDAQ: DNDN). Its stock was down on its own earnings and disappointing Provenge sales figures. With the potential added competition on top of bad results, Dendreon’s stock is off by 35% to $6.77 and shares put in a new 52-week low of $6.56 this morning.

Medivation is up 113% at $35.10 and we are already more than ten-times normal trading volume.

JON C. OGG

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.